{"id":"W4311929403","doi":"10.1016/j.clcc.2022.11.003","title":"ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Regorafenib; Irinotecan; Medicine; Randomized controlled trial; Colorectal cancer; Internal medicine; Oncology; Pharmacology; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003879379,0.0005498833,0.002685584,0.0002139358,0.0006799306,0.00002888274,0.0008315092,0.0004367928,0.003269333],"category_scores_gemma":[0.002479915,0.0004034803,0.0007085465,0.0005265907,0.001216784,0.0001105278,0.001182397,0.002010223,0.00001979668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000752885,"about_ca_system_score_gemma":0.0006492521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009766415,"about_ca_topic_score_gemma":0.001648604,"domain_scores_codex":[0.9916904,0.003768053,0.002398236,0.001026306,0.0002623643,0.0008546631],"domain_scores_gemma":[0.9910913,0.007014284,0.001060897,0.000472991,0.0002455441,0.0001150164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9313425,0.00469873,0.0004227986,0.00002473307,0.001046522,0.00001434778,0.001116267,0.0009790567,0.01967345,0.0000280887,0.002095242,0.03855824],"study_design_scores_gemma":[0.9111818,0.009668548,0.001613905,0.00009741858,0.0005655852,0.00001274138,0.0002743481,0.0003992639,0.02460539,0.00001794207,0.05102055,0.0005424891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747789,0.005841783,0.00003709299,0.002829088,0.008930448,0.006546151,0.0005026276,0.0000624661,0.0004714667],"genre_scores_gemma":[0.9920674,0.001424589,0.00004322689,0.001288884,0.0004459852,0.003221069,0.0000926619,0.00006950228,0.0013467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04892531,"threshold_uncertainty_score":0.9998417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04694934307638858,"score_gpt":0.3620586741039091,"score_spread":0.3151093310275205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}